7.7.6. special situations. 7.7.6.1. impact prior neoadjuvant/adjuvant therapy treatment sequence peri-operative systemic treatment increasingly used uc including cisplatin-based chemotherapy neoadjuvant setting bc adjuvant platinum-based chemotherapy upper tract uc . many ongoing phase iii trials investigate use immunotherapy setting well (see section 7.6.2). far, one trial reported significant dfs benefit adjuvant treatment nivolumab compared placebo whereas one trial reported significant benefit using atezolizumab vs. placebo setting whilst another trial reported negative findings . expected increased number patients metastatic uc received pre-treatment platinum and/or immunotherapy agents. prospective trials investigated treatment patients. choice treatment patients depends applied peri-operative treatment time relapse. least 12 months passed since end peri-operative treatment systemic treatment treatment-naive patients recommended. 7.7.6.2. systemic treatment metastatic disease histology pure urothelial carcinoma pure uc represents predominant histology 90% patients muc. subtypes (e.g. micropapillary, nested, sarcomatoid) divergent differentiation (e.g., scc, adenocarcinoma) found addition pure uc 33% patients. patients often excluded large phase ii phase iii trials therefore knowledge best management patients limited. respective literature reviewed recently expert delphi survey consensus conference provided guidance . case predominant pure uc recommended treat patients mixed histology way patients pure uc histology. patients predominant non-urothelial differentiation small cell neuroendocrine carcinoma, urachal adenocarcinoma, scc adenocarcinoma treated individually.